Most studies of Lactococcus lactis as delivery vehicles of pneumococcal antigens are
focused on the effectiveness of mucosal recombinant vaccines against Streptococcus
pneumoniae in animal models. At present, there are three types of pneumococcal
vaccines: capsular polysaccharide pneumococcal vaccines (PPV), protein-
polysaccharide conjugate pneumococcal vaccines (PCV) and protein-based
pneumococcal vaccines (PBPV). Only PPV and PCV have been licensed. These
vaccines, however, do not represent a definitive solution. Novel, safe and inexpensive
vaccines are necessary, especially in developing countries. Probiotic microorganisms
such as lactic acid bacteria (LAB) are an interesting alternative for their use as vehicles
in pneumococcal vaccines due to their GRAS (Generally Recognized As Safe) status.
Thus, the adjuvanticity of Lactococcus lactis by itself represents added value over the
use of other bacteria, a question dealt with in this review. In addition, the expression of
different pneumococcal antigens as well as the use of oral and nasal mucosal routes of
administration of lactococcal vaccines is considered. The advantages of nasal live
vaccines are evident; nonetheless, oral vaccines can be a good alternative when the
adequate dose is used. Another point addressed here is the use of live versus inactivated
vaccines. In this sense, few researches have focused on inactivated strains to be used as
vaccines against pneumoccoccus. The immunogenicity of live vaccines is better than the
one afforded by inactivated ones; however, the probiotic-inactivated vaccine
combination has improved this matter considerably. The progress made so far in the
protective immune response induced by recombinant vaccines, the successful trials in
animal models and the safety considerations of their application in humans suggest that
the use of recombinant vaccines represents a good short-term option in the control of
pneumococcal diseases.